Psychiatric aspect of most common used cardiological drugs
DOI:
https://doi.org/10.12775/JEHS.2020.10.08.013Keywords
cardiological drugs, mental disorders, side effects, mechanism of actionAbstract
Introduction: The count of psychiatric patients is growing. The same trend it is observed among cardiovascular diseases and metabolic like diabetes. Many people take drugs which may affect on mental state. On the one hand that drugs could have pleotropic mechanism of action which are beginning to use in treatment of psychiatry. The other hand is showed undiscovered field of impact on brain working.
Methods and Aim: Shown the psychiatric aspect, like side effects and unusual use, of the most used cardiological drugs. To do this, research of articles was done with the help of deta bases such as PubMed and Google Scholar.
Results: The most used cardiological drugs are beta blockers, calcium canal blockers, ACE inhibtors, ARBs, nitrats, cilostazol, amiodarone and clonidine In this article it was shown current known about those drugs like mechanism of action and a report of psychiatric clinical trials. Beta-blockers are the most commonly used group of cardiological drugs as the one that significantly affects mental health. Their therapeutic importance has been noted in diseases such as: PTSD or stage fright. It was also long believed that they could make depression worse, but the latest research strongly contradicts this. A positive effect in the treatment of depression can also be obtained by usage of inhibitors of the RAA. Calcium channel blockers are another group of cardiac drugs that are important in the regulation of mood in bipolar disorder. To sum up, a large proportion of cardiac drugs can influence the flow of psychiatric diseases, and the use of them may be clinically desirable in patients with both - cardiac and psychiatric problems.
References
Web Site “Heart Disease and Stroke Statistics-2019 At-a-Glance” [ access 28.07.2020 r.] https://healthmetrics.heart.org/wp-content/uploads/2019/02/At-A-Glance-Heart-Disease-and-Stroke-Statistics-%E2%80%93-2019.pdf
Web Site “Cardiovascular diseases (CVDs)” [Access 28.07.2020 r.] https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
Web Site “ Facts & Figures ” [Access 28.07.2020 r.] http://www.mepheartgroup.eu/index.php/facts-a-figures#CVD1
Web Site „European Cardiovascular Disease Statistics 2017 ” [Access 28.07.2020 r.] http://www.ehnheart.org/cvd-statistics.html
Fuentes AV, Pineda MD, Venkata KCN. Comprehension of Top 200 Prescribed Drugs in the US as a Resource for Pharmacy Teaching, Training and Practice. Pharmacy (Basel). 2018;6(2):43. Published 2018 May 14. doi:10.3390/pharmacy6020043
Web Site “Leading chemical drugs dispensed in England in 2019, by items” Access [28.07.2020 r.] https://www.statista.com/statistics/378445/prescription-cost-analysis-top-twenty-chemicals-by-items-in-england/
Web Site „Ochrona zdrowia w gospodarstwach domowych w 2016 r.” [Access 28.07.2020 r.] https://stat.gov.pl/obszary-tematyczne/zdrowie/zdrowie/ochrona-zdrowia-w-gospodarstwach-domowych-w-2016-r-,2,6.html
Web Site „European Cardiovascular Disease Statistics 2017.” [Access 28.07.2020 r.] http://www.ehnheart.org/cvd-statistics.html
Web Site, “Facts & Figures”, [Access 28.07.2020 r.] http://www.mepheartgroup.eu/index.php/facts-a-figures
Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017;1(1):CD002003. Published 2017 Jan 20. doi:10.1002/14651858.CD002003.pub5
Cruickshank JM. The Role of Beta-Blockers in the Treatment of Hypertension. Adv Exp Med Biol. 2017;956:149-166. doi:10.1007/5584_2016_36
Lefkowitz RJ, Caron MG, Stiles GL. Mechanisms of membrane-receptor regulation. Biochemical, physiological, and clinical insights derived from studies of the adrenergic receptors. N Engl J Med. 1984;310(24):1570-1579. doi:10.1056/NEJM198406143102406
Mahabir M, Ashbaugh AR, Saumier D, Tremblay J. Propranolol's impact on cognitive performance in post-traumatic stress disorder. J Affect Disord. 2016;192:98-103. doi:10.1016/j.jad.2015.11.051
Villain H, Benkahoul A, Drougard A, et al. Effects of Propranolol, a β-noradrenergic Antagonist, on Memory Consolidation and Reconsolidation in Mice. Front Behav Neurosci. 2016;10:49. Published 2016 Mar 14. doi:10.3389/fnbeh.2016.00049
National Clinical Guidelines Centre (UK). Stable Angina: Methods, Evidence & Guidance [Internet]. London: Royal College of Physicians (UK); 2011 Jul. (NICE Clinical Guidelines, No. 126.) 7, Beta blockers vs. calcium channel blockers.
Doran AR, Narang PK, Meigs CY, et al. Verapamil concentrations in cerebrospinal fluid after oral administration. N Engl J Med. 1985;312(19):1261-1262.
Cipriani A, Saunders K, Attenburrow MJ, et al. A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development. Mol Psychiatry. 2016;21(10):1324-1332. doi:10.1038/mp.2016.86
Blake BL, Muehlmann AM, Egami K, Breese GR, Devine DP, Jinnah HA. Nifedipine suppresses self-injurious behaviors in animals. Dev Neurosci. 2007;29(3):241-250. doi:10.1159/000096414
Masri G, Bledsoe K, Palacio C. Characteristics of patients prescribed angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the combination at an urban medical center. MedGenMed. 2007;9(4):40. Published 2007 Nov 20.
Ricci F, Di Castelnuovo A, Savarese G, Perrone Filardi P, De Caterina R. ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - A network meta-analysis. Int J Cardiol. 2016;217:128-134. doi:10.1016/j.ijcard.2016.04.132
Wincewicz D, Juchniewicz A, Waszkiewicz N, Braszko JJ. Angiotensin II type 1 receptor blockade by telmisartan prevents stress-induced impairment of memory via HPA axis deactivation and up-regulation of brain-derived neurotrophic factor gene expression. Pharmacol Biochem Behav. 2016;148:108-118. doi:10.1016/j.pbb.2016.06.010
Rathmann W, Haastert B, Roseman JM, Giani G. Cardiovascular drug prescriptions and risk of depression in diabetic patients. J Clin Epidemiol. 1999;52(11):1103-1109. doi:10.1016/s0895-4356(99)00082-7
Williams LJ, Pasco JA, Kessing LV, Quirk SE, Fernandes BS, Berk M. Angiotensin Converting Enzyme Inhibitors and Risk of Mood Disorders. Psychother Psychosom. 2016;85(4):250-252. doi:10.1159/000444646
Johansen A, Holmen J, Stewart R, Bjerkeset O. Anxiety and depression symptoms in arterial hypertension: the influence of antihypertensive treatment. the HUNT study, Norway. Eur J Epidemiol. 2012;27(1):63-72. doi:10.1007/s10654-011-9641-y
Callender JS, Hodsman GP, Hutcheson MJ, Lever AF, Robertson JI. Mood changes during captopril therapy for hypertension. A double-blind pilot study. Hypertension. 1983;5(5 Pt 2):III90-III93. doi:10.1161/01.hyp.5.5_pt_2.iii90
Edwards JD, Ramirez J, Callahan BL, et al. Antihypertensive Treatment is associated with MRI-Derived Markers of Neurodegeneration and Impaired Cognition: A Propensity-Weighted Cohort Study. J Alzheimers Dis. 2017;59(3):1113-1122. doi:10.3233/JAD-170238
Rojek Agnieszka, Szczęch Radosław. Działania niepożądane nitrogliceryny — konieczność edukacji chorych, Choroby Serca i Naczyń 2006, tom 3, nr 4, 187–192
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64:e1.
Hu Z, Wang L, Ma S, et al. Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease. Alzheimers Dement (N Y). 2018;4:542-555. Published 2018 Oct 14. doi:10.1016/j.trci.2018.09.001
Stuhec M, Keuschler J, Serra-Mestres J, Isetta M. Effects of different antihypertensive medication groups on cognitive function in older patients: A systematic review. Eur Psychiatry. 2017;46:1-15. doi:10.1016/j.eurpsy.2017.07.015
Kim YR, Kim HN, Hong KW, Shin HK, Choi BT. Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke. Psychopharmacology (Berl). 2016;233(6):1055-1066. doi:10.1007/s00213-015-4185-6
Rajagopal S. Catatonic depression precipitated by amiodarone prescribed for atrial fibrillation. Indian J Psychiatry. 2015;57(1):105-106. doi:10.4103/0019-5545.148545
Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm 2007; 4:1250.
Ambrose A, Salib E. Amiodarone-induced depression. Br J Psychiatry. 1999;174:366-367. doi:10.1192/bjp.174.4.366b
Cheesman N, Taylor D. Psychosis and depression associated with alteration to amiodarone therapy. J Psychopharmacol. 2010;24(1):131-133. doi:10.1177/0269881108095717
Foley KT, Bugg KS. Separate episodes of delirium associated with levetiracetam and amiodarone treatment in an elderly woman. Am J Geriatr Pharmacother. 2010;8(2):170-174. doi:10.1016/j.amjopharm.2010.03.001
Schneier FR. Clinical practice. Social anxiety disorder. N Engl J Med. 2006;355:1029–1036.
Okda, A. M., Nasr, M. M., & Amin, S. N. (2018). Between an ugly truth and a perfect lie: Wiping off fearful memories using beta-adrenergic receptors antagonists. Journal of Cellular Physiology. doi:10.1002/jcp.27441.
The incidence of depression in new users of beta-blockers and selected antihypertensives. Gerstman BB, Jolson HM, Bauer M, Cho P, Livingston JM, Platt R J Clin Epidemiol. 1996 Jul; 49(7):809-15.
Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM JAMA. 2002 Jul 17; 288(3):351-7.
Wiseman TA, Curtis K, Lam M, Foster K. Incidence of depression, anxiety and stress following traumatic injury: a longitudinal study. Scand J Trauma Resusc Emerg Med. 2015 Mar 28; 23():29.
Keller S, Frishman WH. Neuropsychiatric effects of cardiovascular drug therapy. Cardiol Rev. 2003 Mar-Apr; 11(2):73-93.
Zhu GH, Sun XP, Li J, et al. No association between low-dose reserpine use and depression in older hypertensive patient: result of a multicenter, cross-sectional study. J Geriatr Cardiol. 2019;16(8):608-613. doi:10.11909/j.issn.1671-5411.2019.08.001.
Dubovsky, S.L. (2018). Applications of calcium channel blockers in psychiatry: pharmacokinetic and pharmacodynamic aspects of treatment of bipolar disorder. Expert Opinion on Drug Metabolism & Toxicology, 15(1), 35–47.
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 616
Number of citations: 0